

CleanCap[®] Reagents

Proven Performance: From Discovery to Therapy

Prolific Publication

CleanCap[®] reagents are the premier mRNA capping technology trusted by scientists around the globe for vaccine and therapeutics development—ranging from clinical to commercial. In the last 7 years, CleanCap technology has been leveraged in hundreds of publications, confirming its position as an industry-leading technology.



700+

Publications in 7 years



5x Increase

Annual Publications
in 2015 vs. 2021



200+

Publications in 2021

A Quality Product Yields Quality Results

When science demands high-quality results for high-impact work, researchers trust their experiments to CleanCap reagents.

>60

High-impact
Journals

13.6

Average Journal
Impact Factor


>85

Nature Family
Publications

>40

Cell Family
Publications

Scientists from **37** countries in **6** continents and **100s** of institutions have used CleanCap reagents to power new discoveries in a range of applications:



- 26% Vaccines**
- 25% Cell & Gene Therapy**
- 23% Infectious Diseases**
- 15% Oncology**
- 11% Stem Cells**

Enabling a New Era of Modernized mRNA Therapeutics Production

Driving Success from the Bench to Bedside— and Everywhere in Between

CleanCap technology is trusted by hundreds of researchers across the globe—from academic institutions to pharmaceutical companies—to support basic science and clinical research efforts in biology, chemistry, and bioengineering.



22/25

Top Global
Universities



10/10

Global Leading
Pharmaceutical Companies

Based on Times Higher Education World Rankings 2022 and Pharma Boardroom 2022 Article, Top 10 Global Pharma Companies 2021.

Revolutionizing mRNA Therapeutics

CleanCap reagents have enabled multiple therapeutics programs through the development process, supporting researchers from early discovery and clinical drug approval, to global manufacture and distribution.




>45

Therapeutic
Programs



>20


Clinical Stage
Global Partnerships



>95kg

CleanCap Reagent
Produced

Supporting the Leading COVID-19 Vaccine Program Around the Globe



>140

Countries with
Approved/Authorized
Vaccines

3

Billion

Doses in
2021 alone

Ready to get started?

[Contact Us](#)

 **TriLink**
BIOTECHNOLOGIES
part of Maravai LifeSciences

©2022 TriLink BioTechnologies. All Rights Reserved.
Ver. 03.25.2022